{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T18:11:57Z","timestamp":1788977517030,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T00:00:00Z","timestamp":1629417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T00:00:00Z","timestamp":1629417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"},{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Asklepios Proresearch"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologe"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Hintergrund<\/jats:title>\n                <jats:p>Intravitreale operative Medikamenteneingaben (IVOM) geh\u00f6ren zu den h\u00e4ufigsten medizinischen Prozeduren \u00fcberhaupt mit ca. 1,5\u00a0Mio. Eingriffen in Deutschland pro Jahr. F\u00fcr diese enorme Versorgungsaufgabe gibt es nur wenige empirische Daten \u00fcber den Versorgungsprozess und seine klinische und subjektive Wirkung.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Material und Methoden<\/jats:title>\n                <jats:p>Es wird die Entwicklung und der Aufbau des Hamburger Registers f\u00fcr intravitreale Injektionstherapien (QIVOM) detailliert beschrieben. IVOM-Patienten der drei gro\u00dfen Augenkliniken Hamburgs (Asklepios Kliniken Nord-Hamburg und Barmbek, Universit\u00e4tsklinikum Hamburg-Eppendorf) werden im Rahmen der Routineversorgung mit IVOM zur Studienteilnahme eingeladen. Es werden subjektive Patientenangaben zum Krankheits- und Behandlungserleben erhoben und diese mit den patientenbezogenen medizinischen Parametern elektronisch erg\u00e4nzt, pseudonymisiert und in einer elektronischen Datenbank erfasst.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ergebnisse<\/jats:title>\n                <jats:p>Von den ersten 162 Studienpatienten (Alter 41\u201395 Jahre) war die Behandlungsindikation bei 64% exsudative altersbedingte Makuladegeneration (AMD), bei 22% retinaler Venenverschluss und bei 11% diabetisches Makula\u00f6dem. Es ergibt sich ein heterogenes Bild der Erkrankungsschwere und der subjektiven Beeintr\u00e4chtigung. Eine Sehsch\u00e4rfe von 0,5 und besser wiesen 31,8% der Patienten am behandelten Auge im Vergleich zu 79,1% am Partnerauge auf. Die gr\u00f6\u00dfte praktische Einschr\u00e4nkung betraf die Lesef\u00e4higkeit, bei der \u00fcber ein Drittel erhebliche Einschr\u00e4nkungen erlebte. Autofahren war immerhin f\u00fcr 62% m\u00f6glich. Eine Verbesserung der Sehf\u00e4higkeit durch IVOM erreichten 45% der Patienten.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Schlussfolgerung<\/jats:title>\n                <jats:p>Die Datenerfassung von patientenseitigen Daten und medizinischer Versorgungsdaten aus den Kliniken stellt den gro\u00dfen Vorteil des neu geschaffenen Registers dar. Die Erweiterung der Datenbasis soll in Zukunft vielf\u00e4ltige weiterf\u00fchrende Erkenntnisse erbringen und zur Qualit\u00e4tssicherung in der IVOM-Therapie beitragen.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00347-021-01454-w","type":"journal-article","created":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T13:02:39Z","timestamp":1629464559000},"page":"280-287","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Das Hamburger Register f\u00fcr intravitreale Injektionstherapien (QIVOM)","The Hamburg register for intravitreal injection therapies (QIVOM)"],"prefix":"10.1007","volume":"119","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1990-4918","authenticated-orcid":false,"given":"Christian","family":"Wolfram","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Schargus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,20]]},"reference":[{"key":"1454_CR1","first-page":"48","volume":"12","author":"M Augustin","year":"2014","unstructured":"Augustin\u00a0M, Spehr\u00a0C, Radtke\u00a0MA et\u00a0al (2014) German psoriasis registry PsoBest: objectives, methodology and baseline data. J\u00a0Dtsch Dermatol Ges 12:48\u201357","journal-title":"J Dtsch Dermatol Ges"},{"key":"1454_CR2","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.2147\/OPTH.S209253","volume":"13","author":"J Callizo","year":"2019","unstructured":"Callizo\u00a0J, Ziemssen\u00a0F, Bertelmann\u00a0T et al (2019) Real-world data: ranibizumab treatment for retinal vein occlusion in the OCEAN study. Clin Ophthalmol 13:2167\u20132179","journal-title":"Clin Ophthalmol"},{"key":"1454_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/OPTH.S151611","volume":"12","author":"C Ehlken","year":"2018","unstructured":"Ehlken\u00a0C, Helms\u00a0M, Bohringer\u00a0D et al (2018) Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients. Clin Ophthalmol 12:13\u201320","journal-title":"Clin Ophthalmol"},{"key":"1454_CR4","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman\u00a0M, Gudex\u00a0C, Lloyd\u00a0A et al (2011) Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 20:1727\u20131736","journal-title":"Qual Life Res"},{"key":"1454_CR5","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00347-019-01005-4","volume":"117","author":"FG Holz","year":"2020","unstructured":"Holz\u00a0FG, Johnson\u00a0KT, Bauer-Steinhusen\u00a0U et al (2020) Eine Untersuchung von Einflussfaktoren auf die Adh\u00e4renz von Patienten mit neovaskul\u00e4rer altersabh\u00e4ngiger Makuladegeneration mithilfe des neu konzipierten Patientenfragebogens LAF-IVT. Ophthalmologe 117:765\u2013774","journal-title":"Ophthalmologe"},{"key":"1454_CR6","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","volume":"99","author":"FG Holz","year":"2015","unstructured":"Holz\u00a0FG, Tadayoni\u00a0R, Beatty\u00a0S et al (2015) Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol 99:220\u2013226","journal-title":"Br J Ophthalmol"},{"key":"1454_CR7","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1136\/bjophthalmol-2015-308166","volume":"100","author":"FG Holz","year":"2016","unstructured":"Holz\u00a0FG, Tadayoni\u00a0R, Beatty\u00a0S et al (2016) Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study. Br J Ophthalmol 100:1623\u20131628","journal-title":"Br J Ophthalmol"},{"key":"1454_CR8","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1016\/j.ophtha.2014.05.006","volume":"121","author":"JF Korobelnik","year":"2014","unstructured":"Korobelnik\u00a0JF, Do\u00a0DV, Schmidt-Erfurth\u00a0U et al (2014) Intravitreal aflibercept for diabetic macular edema. Ophthalmology 121:2247\u20132254","journal-title":"Ophthalmology"},{"key":"1454_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s00347-020-01273-5","author":"A Lommatzsch","year":"2020","unstructured":"Lommatzsch\u00a0A, Eter\u00a0N, Ehlken\u00a0C et al (2020) Adh\u00e4renz bei der anti-VEGF Therapie \u2013 \u00dcberlegungen und praktische Empfehlungen. Ophthalmologe. https:\/\/doi.org\/10.1007\/s00347-020-01273-5","journal-title":"Ophthalmologe"},{"key":"1454_CR10","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.2337\/dc10-0493","volume":"33","author":"P Massin","year":"2010","unstructured":"Massin\u00a0P, Bandello\u00a0F, Garweg\u00a0JG et al (2010) Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a\u00a012-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 33:2399\u20132405","journal-title":"Diabetes Care"},{"key":"1454_CR11","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.ophtha.2011.01.031","volume":"118","author":"P Mitchell","year":"2011","unstructured":"Mitchell\u00a0P, Bandello\u00a0F, Schmidt-Erfurth\u00a0U et al (2011) The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 118:615\u2013625","journal-title":"Ophthalmology"},{"key":"1454_CR12","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1055\/s-0030-1263132","volume":"72","author":"D M\u00fcller","year":"2010","unstructured":"M\u00fcller\u00a0D, Augustin\u00a0M, Banik\u00a0N et\u00a0al (2010) Memorandum Register f\u00fcr die Versorgungsforschung. Gesundheitswesen 72:824\u2013839","journal-title":"Gesundheitswesen"},{"key":"1454_CR13","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00113-016-0176-2","volume":"119","author":"EA Neugebauer","year":"2016","unstructured":"Neugebauer\u00a0EA, Stausberg\u00a0J (2016) Was Register leisten k\u00f6nnen und was nicht: Sicht der AG Register des Deutschen Netzwerks Versorgungsforschung e.\u202fV. (DNVF). Unfallchirurg 119:493\u2013500","journal-title":"Unfallchirurg"},{"key":"1454_CR14","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1038\/s41433-018-0126-z","volume":"32","author":"NCI Nguyen","year":"2018","unstructured":"Nguyen\u00a0NCI, Fabro\u00a0F, Ambresin\u00a0A et al (2018) Factors associated with pain during intravitreal injection of anti-vascular endothelial growth factor. Eye (Lond) 32:1544\u20131546","journal-title":"Eye (Lond)"},{"key":"1454_CR15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s00347-019-0931-1","volume":"117","author":"M Roth","year":"2020","unstructured":"Roth\u00a0M, Holtmann\u00a0C, Bohringer\u00a0D et\u00a0al (2020) Stand und Perspektiven registerbasierter Studien in der deutschen Augenheilkunde. Ophthalmologe 117:36\u201343","journal-title":"Ophthalmologe"},{"key":"1454_CR16","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/aos.12802","volume":"94","author":"O Segal","year":"2016","unstructured":"Segal\u00a0O, Segal-Trivitz\u00a0Y, Nemet\u00a0AY et al (2016) Anxiety levels and perceived pain intensity during intravitreal injections. Acta Ophthalmol 94:203\u2013204","journal-title":"Acta Ophthalmol"},{"key":"1454_CR17","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ajo.2017.03.005","volume":"177","author":"H Senra","year":"2017","unstructured":"Senra\u00a0H, Balaskas\u00a0K, Mahmoodi\u00a0N et al (2017) Experience of anti-VEGF treatment and clinical levels of depression and anxiety in patients with wet age-related macular degeneration. Am J Ophthalmol 177:213\u2013224","journal-title":"Am J Ophthalmol"},{"key":"1454_CR18","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/eye.2017.271","volume":"32","author":"S Sii","year":"2018","unstructured":"Sii\u00a0S, Aspinall\u00a0P, Borooah\u00a0S et al (2018) Exploring factors predicting changes in patients\u2019 expectations and psychosocial issues during the course of treatment with intravitreal injections for wet age-related macular degeneration. Eye (Lond) 32:673\u2013678","journal-title":"Eye (Lond)"},{"key":"1454_CR19","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1055\/a-1083-6417","volume":"82","author":"J Stausberg","year":"2020","unstructured":"Stausberg\u00a0J, Maier\u00a0B, Bestehorn\u00a0K et\u00a0al (2020) Memorandum Register f\u00fcr die Versorgungsforschung: Update 2019. Gesundheitswesen 82:e39\u2013e66","journal-title":"Gesundheitswesen"},{"key":"1454_CR20","doi-asserted-by":"publisher","first-page":"e942","DOI":"10.1111\/aos.13771","volume":"96","author":"J Stefanickova","year":"2018","unstructured":"Stefanickova\u00a0J, Cunha-Vaz\u00a0J, Ulbig\u00a0M et al (2018) A noninterventional study to monitor patients with diabetic macular oedema starting treatment with ranibizumab (POLARIS). Acta Ophthalmol 96:e942\u2013e949","journal-title":"Acta Ophthalmol"},{"key":"1454_CR21","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s00417-020-04803-8","volume":"259","author":"J Wachtlin","year":"2021","unstructured":"Wachtlin\u00a0J, Eter\u00a0N, Hasanbasic\u00a0Z et al (2021) Importance of continuous treatment with intravitreal aflibercept injections in patients with neovascular age-related macular degeneration-12-month post hoc analysis of the PERSEUS real-world evidence study. Graefes Arch Clin Exp Ophthalmol 259:601\u2013611","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1454_CR22","first-page":"341","volume":"32","author":"M Wenzel","year":"2020","unstructured":"Wenzel\u00a0M, Scharrer\u00a0A, Schayan\u00a0K, Agostini\u00a0H, Reinhard\u00a0T (2020) Ambulante und station\u00e4re Intraokularchirurgie 2019: Ergebnisse der aktuellen Umfrage von BDOC, BVA, DGII und DOG. Ophthalmochirurgie 32:341\u2013350","journal-title":"Ophthalmochirurgie"},{"key":"1454_CR23","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1111\/aos.13539","volume":"95","author":"I Westborg","year":"2017","unstructured":"Westborg\u00a0I, Granstam\u00a0E, Rosso\u00a0A et al (2017) Treatment for neovascular age-related macular degeneration in Sweden: outcomes at seven years in the Swedish macula register. Acta Ophthalmol 95:787\u2013795","journal-title":"Acta Ophthalmol"},{"key":"1454_CR24","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jagp.2013.01.076","volume":"22","author":"B Wild","year":"2014","unstructured":"Wild\u00a0B, Eckl\u00a0A, Herzog\u00a0W et al (2014) Assessing generalized anxiety disorder in elderly people using the GAD\u20117 and GAD\u20112 scales: results of a\u00a0validation study. Am J Geriatr Psychiatry 22:1029\u20131038","journal-title":"Am J Geriatr Psychiatry"},{"key":"1454_CR25","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00347-015-0099-2","volume":"113","author":"F Ziemssen","year":"2016","unstructured":"Ziemssen\u00a0F, Bertelmann\u00a0T, Hufenbach\u00a0U et al (2016) Verz\u00f6gerung des Behandlungsbeginns um mehr als 2\u00a0Wochen. Relevanz f\u00fcr m\u00f6glichen Visusgewinn nach Anti-VEGF-Therapie unter Real-Life-Bedingungen (Interimanalyse der prospektiven OCEAN-Studie). Ophthalmologe 113:143\u2013115","journal-title":"Ophthalmologe"}],"container-title":["Der Ophthalmologe"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-021-01454-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-021-01454-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-021-01454-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T09:06:54Z","timestamp":1646730414000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00347-021-01454-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,20]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["1454"],"URL":"https:\/\/doi.org\/10.1007\/s00347-021-01454-w","relation":{},"ISSN":["0941-293X","1433-0423"],"issn-type":[{"value":"0941-293X","type":"print"},{"value":"1433-0423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,20]]},"assertion":[{"value":"14 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"C.\u00a0Wolfram und M.\u00a0Schargus geben an, dass das Registerprojekt QIVOM derzeit gef\u00f6rdert wird durch Forschungsgelder von Novartis Pharma sowie von Asklepios Proresearch.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}